The IL-7R pathway is a major driver of ALL, and in vitro studies have shown that the JAK1/2 inhibitor ruxolitinib inhibits ligand-independent signaling and induces death in transformed cell lines. Here, IL7R is linked to acute lymphoblastic leukemia.